Efficacy and safety of tegoprazan‐ and rabeprazole‐based concomitant therapies for <scp><i>Helicobacter pylori</i></scp> infection: Real‐world evidence
Tegoprazan- and rabeprazole-based concomitant therapies for H. pylori eradication showed comparable efficacy and overall safety. The effect of tegoprazan on dose increases or other regimens, such as bismuth-containing quadruple therapy, should be further evaluated, because the efficacy of tegoprazan-based concomitant therapy may be suboptimal in regions where the clarithromycin resistance rate is high.
Authors
- Yoon Suk Jung (ORCID: https://orcid.org/0000-0002-1963-7170)
- Byung Wook Jung (ORCID: https://orcid.org/0000-0002-8942-4031)
- Chan Hyuk Park (ORCID: https://orcid.org/0000-0003-3824-3481)
Institutions
- Yonsei University (KR)
- Kangbuk Samsung Hospital (KR)
- Hanyang University Guri Hospital (KR)
- Chung-Ang University Hospital (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Journal of Gastroenterology and Hepatology
- Published
- 2024-08-26
- DOI
- https://doi.org/10.1111/jgh.16719
- Citations
- 4
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 2.29